STUDresearch · Non-peptide
SLU-PP-915
Also known as
SLU PP 915 · SLUPP915 · 915 · SLU-PP 915 · SLU-PP915 · oral ERR pan-agonist (915) · compound 10s (boronic acid pan-ERR) · 915 ERR agonist
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Lots of talk
Systemic
Oral
Metabolic research compounds
Systemic — pan-ERR small molecule (ERRα/β/γ) aimed at aerobic/exercise-mimetic gene programs in muscle, heart, and other high-energy tissues.
What people say
SLU-PP-915 is a small-molecule pan-ERR agonist developed as an orally active follow-on to SLU-PP-332. Exercise-capacity and gene-expression findings are from mice; no published human trial or gray-market safety package establishes outcomes.
Doses people talk about
Rows describe separate animal and unverified community contexts, not a progression or mouse-to-human conversion. Oral and intraperitoneal exposures are not interchangeable.
How it may feel
Inspected reports conflict and are heavily confounded: a 20 mg daily plus BAM15 account described endurance and focus alongside slower recovery and midday fatigue, while a 30 mg twice-daily account described easier cardio and end-of-day exhaustion. Product identity was unverified.
Inspected stacked report20 mg oral once daily
A day-20 report also used BAM15 and described benefits and problems, so attribution and product identity remain unresolved.
Inspected split report30 mg oral twice daily
Another commenter described morning and noon use with easier cardio and marked later fatigue; no assay or controlled comparator was provided.
Mouse discovery exposure20 mg/kg IP once
Used for acute gene induction and treadmill testing in male mice; not a human dose.
Mouse oral study range0.2–32 mg/kg oral or IP
Male mice received once- or twice-daily dosing for up to seven days; route and dose were experimental variables.
Half-life & effect duration
- Half-life in the body
- Oral · miceAbout 18–28 minutes
- Human useNo settled estimate
- Liver-cell stability testOver 60 minutes
- Felt duration people report
- Positive reportsEndurance, focus or easier cardio
- Other experiencesLater fatigue, end-of-day exhaustion or recovery complaints
Cycles people discuss
Community experiments are usually framed as two-to-eight-week blocks with inconsistent off periods. These informal experiments are not human dose-finding, and the seven-day mouse regimen is not a clinical cycle.
Timing
Community notes describe pre-training use about 20 minutes before activity, sometimes split between cardio and lifting; one inspected oral account instead used waking and noon doses. Fasted use and taking it with food for reflux both appear. These are inconsistent reported habits, not a standardized human schedule.
Stacks
Solo use is discussed as the cleaner comparison. Reports with BAM15, MOTS-c, 5-Amino-1MQ or GLP-1 drugs cannot isolate 915's effects or adverse symptoms.
Access talk
RUO research chem — oral capsules/powder, not a compounded pharmacy ERR pill and not an approved exercise drug.
Watch for
Unknown human safety: No mature human AE database or Phase 1 package for gray-market 915.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
Oral SLU-PP-915 plasma half-life was 18–28 minutes in male mice.
Billon et al. measured concentration-time profiles after 2, 8 and 32 mg/kg oral gavage; repeated 32 mg/kg twice daily for seven days did not accumulate at the one-hour comparison.
Mouse oral PK does not establish human elimination, gray-market identity, oral bioavailability percentage or a human redosing interval.
- Billon et al. — An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity (opens in a new tab)Primary mouse study used 0.2–32 mg/kg orally or intraperitoneally, measured an 18–28 minute oral plasma half-life, tested seven-day repeated dosing and reported exercise-capacity and Ddit4 outcomes.Small male-mouse experiments; no human PK, efficacy, safety or gray-market identity testing.
Half-life in the body
A human parent-plasma half-life was not established by the reviewed sources.
The available primary program is medicinal chemistry and mouse pharmacology; the greater-than-60-minute discovery value is an in-vitro microsomal stability result.
No numerical human value is inferred from mouse PK, microsomes, community schedules or vendor claims.
- Hampton et al. — Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915 (opens in a new tab)Primary medicinal-chemistry and mouse paper identifies compound 10s as SLU-PP-915, reports pan-ERR activity, in-vitro microsomal stability and in-vivo target-gene induction.Cell and mouse work; the microsomal stability value is not a human body half-life or a clinical safety result.
- Billon et al. — An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity (opens in a new tab)Primary mouse study used 0.2–32 mg/kg orally or intraperitoneally, measured an 18–28 minute oral plasma half-life, tested seven-day repeated dosing and reported exercise-capacity and Ddit4 outcomes.Small male-mouse experiments; no human PK, efficacy, safety or gray-market identity testing.
Felt duration people report
The inspected reports do not establish a consistent onset or duration of perceived effects.
A 20-day stacked report described endurance and focus with later fatigue and recovery complaints; another author using 30 mg twice daily described easier cardio and end-of-day exhaustion, while the deleted-author thread centered on identity and dose disagreement.
Anonymous reports, unverified products, BAM15 and other confounding, self-selection and no blinded comparator prevent causal or prevalence estimates.
- Reddit r/SLUPP332 — Slu-pp-915 (opens in a new tab)Multiple authors discuss scarce product access; one reports 20 mg daily with BAM15 for 20 days, another 30 mg on waking and at noon, with differing endurance, fatigue and recovery experiences.Anonymous multi-author discussion, unverified compounds, major stack and training confounding, no laboratory confirmation or control group.
- Reddit r/Biohackers — 20MG SLU-PP-915 Experiment (opens in a new tab)Deleted-author post retains comments questioning product identity and debating 2 mg, 20 mg and much higher extrapolations; the author called the dosing guessed and a four-week experiment.Original post deleted, author identity unavailable, comments conflict, products were unverified and mouse-to-human extrapolations were not clinical dose finding.
Other context in this card
- Billon et al. — Synthetic ERR alpha/beta/gamma agonist induces an ERR alpha-dependent acute aerobic exercise response and enhances exercise capacity (opens in a new tab)Primary mouse study reports SLU-PP-332 30 mg/kg IP exposure sampling and 25–50 mg/kg IP efficacy regimens, including twice-daily schedules.Different molecule and mouse route; comparator evidence cannot define a human or SLU-PP-915 dose.
What people say
- Bro pitch vs 332: “Same exercise-mimetic vibe, better oral story” — fewer pure “oral 332 did nothing” dead-ends if identity is real. forum
- Endurance / fat-ox talk: Grouped with 332, MOTS-c, cardarine-style threads for zone-2 stamina and cut-phase oxidation chatter. forum
- Honesty: Stronger route/PK story than proven human fat-loss or VO2 numbers; human outcomes remain anecdote-heavy. forum
- Aerobic capacity (preclinical oral + IP): Billon et al. report that oral SLU-PP-915 enhances aerobic exercise capacity; IP efficacy similar to 332, with oral efficacy maintained when adjusted for systemic exposure. trial
- Treadmill numbers (mice): Community/secondary summaries of the oral paper cite roughly ~50% improvements in running distance and time vs vehicle in some treadmill setups; treat as animal data, not human PRs. animal
- Acute gene program: Upregulates exercise-linked ERR targets including PGC-1α, PDK4, LDHA, DDIT4/Ddit4 in muscle models; Ddit4 can match or exceed a bout of treadmill running depending on muscle. animal
- Early IP characterization (Hampton 2023): Single 20 mg/kg IP raised DDIT4, PDK4, and PGC1α in quadriceps within ~1 h and increased running distance/time vs vehicle. animal
- Mitochondrial signals: Repeated oral work associated with higher mitochondrial DNA content and mitochondrial gene expression in skeletal muscle models. animal
- Heart-failure models: Xu et al. (Circulation): pan-ERR agonists 332 and 915 improved ejection fraction, ameliorated fibrosis, and increased survival in pressure-overload HF without changing hypertrophy; metabolomics pointed at fatty-acid / TCA–OXPHOS normalization. animal
- Metabolic-disease positioning (authors): Papers position oral ERR agonists for research into obesity, T2D/MASH-type disease, HF, sarcopenia, and muscular dystrophies — still preclinical framing. trial
Doses people talk about
- Allometric noise (forums): Naive mouse→human conversions from 20 mg/kg IP are argued in threads (e.g. ~114 mg for 70 kg after ÷12.3) — still not a human protocol, and oral F is not 100%. forum
- Inspected oral reports: One commenter described 20 mg once daily for 20 days while also using BAM15; another described 30 mg on waking and again at noon. A separate deleted-author thread preserved a 20 mg capsule claim and direct disagreement that 2 mg was already high versus 20 mg being too low. These are unverified, conflicting reports, not a human dose standard. forum
- Low-mg vs high-mg fight: Some users call 2 mg “already high”; others call 20 mg too low and float ~100 mg tablet goals based on scaled mouse exposure — no consensus, no PK validation. forum
- Influencer “915 dosing is lower” claim: Some content says 915 oral doses are typically lower than the high-oral-mg 332 culture because of better oral F — marketing-adjacent, not trial data. forum
- Don’t copy 332 mcg charts: Retail 250 mcg–1 mg oral 332 culture is a different molecule with a published oral-bioavailability problem; 915 is not the same chart. forum
- Split dosing: BID appears in mouse ERR work and some community metabolic-chem habits; human 915 schedules are not standardized. forum
- Stack dose inflation: Avoid stacking 332+915 “for more ERR” without a reason — dual pan-agonism is speculation and multiplies unknown risk. forum
- 2026 X poll split (not a protocol): One August 2026 researcher poll (116 votes) landed ~34% at 1 mg, ~24% at 10 mg, ~26% at 20 mg, ~16% other — half of that poll sat at 10 mg or higher. A smaller range poll still scattered 0–1 / 2–10 / 11–20 mg. forum
- Pre-workout micro camp: 250–500 mcg oral ~20 min pre-session shows up in early n=1 notes — a different planet from the 10–20 mg capsule camp. anecdote
- ~2 mg + 2 mg training-day split: 2026 logs using ~2 mg before fasted cardio and ~2 mg before the lift are a third camp — still not a shared chart. anecdote
- 10 mg capsule SKUs: Gray-market bottles labeled 10 mg/cap are a 2026 retail unit people actually post COAs for — labeled mg is still not proven human PK. forum
- Identity before dose: Multiple threads claim Chinese OEM zero real production early on and demand Jano/COA proof — labeled mg is meaningless if the powder is not 915. forum
- Framing: All human figures below are research-chem / community discussion — not clinical dosing, not advice, not for consumption. forum
- Mouse IP (discovery): Hampton et al. used 20 mg/kg IP for acute gene induction and treadmill capacity. animal
- Mouse oral/IP range (oral paper): Billon oral-activity work is summarized as testing ~0.2–32 mg/kg SLU-PP-915 by oral or intraperitoneal routes (dose-ranging / PK–performance context). animal
- vs 332 mouse culture: 332 efficacy papers often used higher IP loads (commonly discussed as ~25–50 mg/kg, sometimes BID); 915 oral paper claims comparable performance at lower relative doses in some head-to-heads. animal
How it may feel
- Hours 1–6 (theory vs logs): Mouse gene readouts move within ~1 h of IP; human “same-day feel” is inconsistent — some report warmth/energy, many report nothing acute. forum
- Days 1–7: Oral logs mixed; expectation is less “dead capsule” than oral 332, but purity/identity dominate early nulls. forum
- Weeks 2–4 inspected reports: At day 20 on 20 mg daily plus BAM15, one author reported better endurance and focus but longer recovery, midday nodding and tendon or shoulder complaints. Another author using 30 mg twice daily described easier cardio and end-of-day exhaustion. Unverified products and co-compounds prevent attribution to 915. anecdote
- 4-week “experiment” culture: Some biohacker logs deliberately run ~4 weeks oral capsules (e.g. 20 mg capsule experiments discussed on forums) then reassess. anecdote
- vs oral 332: Dominant bro lore — oral 332 often labeled placebo-risk; 915 is the molecule people switch to after “wasted money on oral 332.” forum
- vs inject 332: Some still prefer injectable 332 culture (closer to published IP pharmacology); 915 is marketed/discussed for oral convenience. forum
- Heat / “always warm” class talk: Shared with high-dose 332 anecdotes — flushed or over-spun feel when dose is aggressive. anecdote
- Pre-training microdose n=1 (2026): Early oral logs at ~250–500 mcg ~20 min before training describe a mild “ran hot” / semi-stim feel, later couch crash, arm tingling and acid reflux at the higher of those two — caffeine confounded. anecdote
- Cardio day vs lift day: 2026 diaries often feel nothing dramatic on a pull/strength day and look for the signal on zone-2 / cardio instead — “not feeling it in the gym” is not treated as proof the ERR program is off. forum
- Low-mg split logs: Some 2026 X n=1s run ~2 mg before fasted cardio and ~2 mg before lifting and report easier stamina, harder-to-hit zone-2, lower resting HR/BP talk, and stimulants feeling stronger/longer — still n=1. anecdote
- Null is still common: Plenty of 2026 replies stay “rodents only / I felt nothing.” Identity, dose camp, and whether they actually did cardio are the usual first arguments. forum
- Week 1 oral PK context (mice): Secondary summaries of the oral paper note 7-day repeated oral dosing with dose-proportional plasma and no obvious excessive accumulation — animal only. animal
Around the dose
- Clock: Pre-training is the 2026 habit — ~20 min before the session in microdose logs; some split a morning cardio cap and a later lifting cap. Not a night peptide in current talk. forum
- Training: People who swallow it then sit still are first to call it “nothing.” Cardio / zone-2 days are where diaries look; strength-only days are often labeled flat. forum
- Food: Fasted-cardio pairing shows up; others swallow with food for reflux. No locked meal ritual. forum
- After: Keep the actual aerobic work in the block. Mouse oral work was additive with training, not a couch replacement. forum
- Don’t dual-ERR: 2026 advice is usually oral 915 *or* inject 332, not both pan-agonists the same day. forum
- Stims: A subset says caffeine/pre-workouts feel stronger or last longer on 915 days — more reason not to stack unknowns and then blame the ERR. anecdote
Cycles people discuss
- Research blocks: Community often mirrors other metabolic research chems — weeks-long experiments, not multi-year continuous use science. forum
- 2–4 week first look: Common length for “does oral 915 do anything for me” self-logs. forum
- 4–8 week talk: Typical extended cut/endurance experiment length in the class when people keep going past a null first week. forum
- Off periods: Inconsistent; no established human on/off science for 915. forum
- Switching from 332: “Failed oral 332 → try 915” is a recurring story pattern — selection bias heavy. anecdote
- Wait-for-data camp: Some experienced users advise staying on better-characterized 332 inject culture until more real 915 feedback and testing exist. forum
- Continuous daily vs pulsed: Both discussed; no consensus schedule. forum
- Mouse chronic context: Oral paper includes multi-day (e.g. ~7-day) oral regimens for performance/gene endpoints; HF work used multi-week disease models — not human cycles. animal
Timing
- Human half-life / oral F%: No solid public human PK package for gray-market material. forum
- Oral design goal: Better oral exposure than parent 332 is the published rationale for 915. trial
- 332 problem (papers + bro): Billon oral paper states 332 “lacks oral bioavailability” — that sentence is the root of “oral 332 = placebo” lore. trial
- 915 oral efficacy claim: Authors report oral 915 maintains exercise-capacity benefits when systemic exposure is accounted for. trial
- Measured mouse oral PK: In the Billon study, oral gavage at 2, 8 and 32 mg/kg produced dose-proportional exposure and a plasma half-life of 18–28 minutes. Repeated 32 mg/kg oral dosing twice daily for seven days did not accumulate versus an acute dose at the one-hour sample. This is mouse PK, not a human clock. animal
- Accumulation (mice): Repeated oral dosing summarized as no excessive accumulation over a short multi-day window. animal
- Microsomal stability (discovery): Boronic-acid analog 10s (915) showed T½ > 60 min in both mouse and human liver microsomes in the Hampton SAR paper — in vitro only. lab
- Acute gene timing: Muscle ERR targets elevated by ~1 h after 20 mg/kg IP in mice. animal
- Downstream programs: Nuclear-receptor gene programs (mitochondrial, FAO, Ddit4 axis) may outlast peak plasma — model biology, not a human “how often to redose” rule. trial
- Why multi-dose talk persists: Short practical coverage after rapid clearance in rodents drives BID habits in the ERR class — extrapolated, not proven in humans. animal
More on what it is
- Bro headline: “The oral ERR / 332 that actually works orally” — research-chem and fitness chatter frames 915 as the fix for dead oral-332 capsules. forum
- What it is not: Not cardarine (PPAR), not a SARM, not caffeine, not a peptide, not an approved drug, not a full training replacement. forum
- Pair with 332 card: Read both — bro talk constantly confuses names, doses, and routes. forum
- What it is: Synthetic pan-ERR agonist (ERRα/β/γ) from the Saint Louis University / Burris lab series — a small molecule, not a peptide. Internal chem ID often cited as 10s (boronic-acid–containing 2,5-disubstituted thiophene amide). trial
- Why it exists: Designed as a chemically distinct, orally bioavailable follow-on after SLU-PP-332 proved useful in mice but lacked oral bioavailability (explicit rationale in the Billon oral-activity paper). trial
- How it is supposed to work (plain): ERR nuclear receptors drive mitochondrial biogenesis, fatty-acid oxidation, and oxidative phosphorylation gene programs; agonism is pitched as an exercise-mimetic transcriptional push, not a stimulant. trial
- Evidence level: Animal pharmacology + medicinal chemistry papers; no published human RCTs for gray-market use. trial
- Chemistry note: Boronic acid H-bond-donor swap was used to keep potency and improve microsomal stability vs phenol analogs in the discovery series. trial
Stacks
- Solo oral experiment first: Often recommended in discussion so any effect (or null) is not blamed on a 5-compound cut stack. forum
- With SLU-PP-332: Compared constantly; rarely a good reason to run both — same target family. forum
- Failed oral 332 → 915 switch: Common narrative stack path (sequential, not simultaneous). anecdote
- Metabolic adjacency: Discussed next to MOTS-c, 5-Amino-1MQ, BAM15, and GLP-1 lifestyle contexts — confounded. forum
- Endurance adjacency: Cardarine (GW501516) / other “exercise mimetic” threads sit next to 915 talk. forum
- NAD support chatter: NMN/NR/NAD+ sometimes listed alongside mitochondrial-leaning stacks. forum
- Training required: Even bro content usually says it does not replace cardio; mouse work often pairs compound with treadmill protocols. forum
- Avoid dual-ERR load stacking: 332+915 same-day is speculative overkill in community risk talk. forum
- Mito kitchen-sink (2026 X): MOTS-c + NAD+ + methylene blue + 915 shows up as a “you will feel it” screenshot stack — attribution is mush. forum
- ATX-304 / O-304 adjacency: 2026 threads draw an AMPK → PGC-1α / ERR Venn diagram and add ATX on a different day rather than stacking two unknowns at once. forum
- 5-Amino-1MQ / SS-31 cut stacks: Named next to 915 in the same metabolic-chem month; contest-prep logs still credit deficit and cardio first. forum
Access talk
- RUO research chem — oral capsules/powder, not a compounded pharmacy ERR pill and not an approved exercise drug. forum
- 2026 shelf unit: 10 mg capsules with posted COAs are a common gray-market SKU; 332 oral bottles are the thing people are trying to leave. forum
- Identity risk: New hot name + mixed 1 mg vs 20 mg camps = easy mislabel / underfill. Threads still ask for independent assay, not a vendor screenshot. forum
- Don’t read mouse oral-F as a human product: Billon 2025 is why 915 is sold as the swallow; it is not a human dose label. trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Unknown human safety: No mature human AE database or Phase 1 package for gray-market 915. forum
- Identity / fake risk: New hot molecule + high price = elevated mislabel risk (wrong chem, underdose, or non-915 powder sold as 915). Forum OEM “zero production” claims amplify this. forum
- Class thermal / energy sides: Heat, sweating, “wired then flat” talk appears in ERR/exercise-mimetic community logs (often from 332 culture and assumed class overlap). anecdote
- Sleep: Late aggressive dosing sometimes linked to worse sleep in metabolic-chem anecdotes — inconsistent. anecdote
- GI: High oral mg small-molecule capsules can upset stomach in general research-chem practice. forum
- Drug interactions: Unknown with common meds — forums are not PK studies. forum
- Overpromise: “Cardio in a pill / burn fat while lazy” marketing exceeds evidence. forum
- Don’t dual-ERR blindly: 332+915 stacking multiplies unknown exposure without clear upside. forum
- Estrogen-name confusion: ERR ≠ estrogen receptor therapy; still, uninformed “estrogen agonist” panic shows up in threads — mechanism is orphan nuclear receptor, not classic ER HRT. forum
- Reflux / taste: Early oral n=1s mention acid reflux and a bad taste — GI is a real quit reason at any camp. anecdote
- Tingling / over-stim: Arm tingling and a stim-like edge at even 500 mcg oral in one 2026 log; easy to confound with pre-workout caffeine. anecdote
- RHR / “can’t get into z2”: Some 2026 logs like a lower resting HR and then complain zone-2 is harder to stay in — wearable talk, not a cardiac clearance. anecdote
- COA theater: 10 mg capsule assays circulate on X; a PDF is not a human PK study and does not make a second vendor’s powder the same molecule. forum
- Not approved / research-only: Investigational tool compound — not an approved exercise or weight-loss drug. trial
- Cardiac context is dual-edged: Preclinical HF papers show protective signals (EF, fibrosis, survival) under disease models — that is not the same as proven safety for healthy humans pushing performance doses. Long-term cardiac risk in self-experimenters remains open. animal
- Doping / anti-doping interest: In vitro metabolism papers map Phase-I metabolites of 915 (and 332) for analytical detection; performance-mimetic class draws sports-testing attention. trial
- Listen to body: Stop experimental research chem if red-flag symptoms appear — still not medical advice. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.